Search Result
Results for "
cholesterol synthesis
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
9
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W020033
-
|
Endogenous Metabolite
|
Neurological Disease
|
Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol suppresses the aggregation and cytotoxicity of misfolded proteins linked with neurodegenerative diseases .
|
-
-
- HY-N3925
-
|
Bacterial
|
Infection
Metabolic Disease
Inflammation/Immunology
|
Ganoderol A is a terpenoid extracted from Ganoderma lucidum with antimicrobial activities. Ganoderol A inhibits cholesterol synthesis pathway and has significant anti-inflammatory activity and protection against ultraviolet A (UVA) damage .
|
-
-
- HY-125713
-
|
Glucosidase
Enterovirus
|
Infection
|
Ganoderic acid Y is a α-glucosidase inhibitor with an IC50 of 170 μM for yeast α-glucosidase. Ganoderic acid Y inhibits enterovirus 71 (EV71) replication through blocking EV71 uncoating .
|
-
-
- HY-17502
-
-
-
- HY-113486S1
-
-
-
- HY-113486S
-
|
Endogenous Metabolite
|
|
(S)-Lathosterol-d4 is the deuterium labeled (S)-Lathosterol. Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis[1].
|
-
-
- HY-113486
-
-
-
- HY-W020033S
-
-
-
- HY-156197
-
-
-
- HY-124265
-
|
Endogenous Metabolite
|
Metabolic Disease
|
4β-hydroxy Cholesterol is a major oxysterol cholesterol metabolite and a precursor in the synthesis of bile acids that is found in human circulation .
|
-
-
- HY-N2221
-
|
|
|
Ganoderal A, an oxygenated sterol from G. lucidum, is a cholesterol synthesis inhibitor .
|
-
-
- HY-16166
-
-
-
- HY-121795
-
|
HMG-CoA Reductase (HMGCR)
|
Cardiovascular Disease
|
Pravastatin lactone is a potent HMG-CoA inhibitor. Pravastatin Lactone is a metabolite of pravastatin. Pravastatin lactone reduces blood cholesterol levels by inhibiting cholesterol synthesis .
|
-
-
- HY-125666
-
|
Others
|
Infection
|
Agistatin B, isolated from fungus, is a mycotoxin. Agistatin B inhibits cholesterol synthesis .
|
-
-
- HY-113486R
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Lathosterol(Standard) is the analytical standard of Lathosterol. This product is intended for research and analytical applications. Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis.
|
-
-
- HY-114294A
-
|
Biochemical Assay Reagents
|
Metabolic Disease
|
DL-3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) disodium is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor .
|
-
-
- HY-104081
-
Cholestyramine resin; Colestyramine
|
Others
|
Cardiovascular Disease
|
Cholestyramine (Colestyramine) is a bile acid binding resin and can inhibit intestinal bile acid absorption which results in the increasing bile acid synthesis from cholesterol.
|
-
-
- HY-129098
-
DMHCA
1 Publications Verification
|
LXR
|
Metabolic Disease
|
DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects and can be used for the research of cholesterol homeostasis diabetes .
|
-
-
- HY-113037
-
Farnesyl diphosphate
|
TRP Channel
Endogenous Metabolite
|
Neurological Disease
|
Farnesyl pyrophosphate (Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .
|
-
-
- HY-113037C
-
Farnesyl diphosphate ammonium
|
TRP Channel
Endogenous Metabolite
|
Neurological Disease
|
Farnesyl Pyrophosphate ammonium salt, a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate ammonium salt is a TRPM2 (TRP Channel) agonist, and activates TRPM2 opening for ion influx. Farnesyl pyrophosphate ammonium salt is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .
|
-
-
- HY-124265S2
-
|
Endogenous Metabolite
|
Metabolic Disease
|
4β-Hydroxycholesterol-d4 is the deuterium labeled 4β-Hydroxycholesterol. 4β-hydroxy Cholesterol is a major oxysterol cholesterol metabolite and a precursor in the synthesis of bile acids that is found in human circulation[1][2].
|
-
-
- HY-N1214
-
Super Squalene; trans-Squalene; AddaVax
|
|
|
Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-N0686
-
-
-
- HY-124265S1
-
-
-
- HY-106539
-
|
Others
|
Metabolic Disease
Cancer
|
Colesevelam (hydrochloride) is a bile acid sequestrant that bind bile acids in the gut. Colesevelam (hydrochloride) inhibits bile acid reabsorption, leading to increased bile acid synthesis and reduced cholesterol levels in patients with cholestatic pruritus and Crohn’s disease.
|
-
-
- HY-123349
-
|
Drug Metabolite
|
Cardiovascular Disease
|
5α-Hydroxy-6-keto cholesterol is major metabolite of β-epoxide (5α,6β-epoxycholesterol) during direct exposure of intact cultured human bronchial epithelial cells (16-HBE) to ozone. 5α-Hydroxy-6-keto cholesterol inhibits cholesterol synthesis with an IC50 of 350 nM .
|
-
-
- HY-P5282
-
|
Liposome
|
Others
|
ApoA-I mimetic peptide (PVLDLFRELLNELLEALKQKLK) has good lecithin:cholesterol acyl transferase (LCAT) activation potency. ApoA-I mimetic peptide can be used for synthesis of peptide/lipid complex .
|
-
-
- HY-N1214S
-
Super Squalene-d6; trans-Squalene-d6; AddaVax-d6
|
Isotope-Labeled Compounds
|
Others
|
Squalene-d6 is a deuterium labeled Squalene. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-B0144AS1
-
NK-104-d5 sodium
|
Apoptosis
HMG-CoA Reductase (HMGCR)
Mitophagy
Autophagy
|
Metabolic Disease
Cancer
|
Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
|
-
-
- HY-163452
-
|
Others
|
Metabolic Disease
|
Squalene synthase-IN-2 (comppund isomer A-(1S, 3R)-14i) is an orally active squalene synthase inhibitor with IC50 values of 3.4, 99 nM for squalene synthase and cholesterol synthesis, respectively. Squalene synthase-IN-2 reduces plasma cholesterol and triglyceride .
|
-
-
- HY-135383B
-
|
Others
|
Metabolic Disease
|
(Z)-Pitavastatin calcium is the Z-Isomer of Pitavastatin hemicacium. Pitavastatin calcium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin calcium inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells .
|
-
-
- HY-B0144A
-
NK-104
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
-
- HY-B0144B
-
NK-104 sodium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Pitavastatin (NK-104) sodium is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin sodium inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin sodium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin sodium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
-
- HY-B0144S
-
NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium
|
Isotope-Labeled Compounds
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Metabolic Disease
Cancer
|
Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
|
-
-
- HY-N7392
-
|
Biochemical Assay Reagents
|
Metabolic Disease
|
Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids .
|
-
-
- HY-B0144
-
NK-104 hemicalcium; Pitavastatin hemicalcium
|
HMG-CoA Reductase (HMGCR)
Autophagy
Mitophagy
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
|
-
-
- HY-150407
-
|
Ligands for Target Protein for PROTAC
Autophagy
|
Others
Neurological Disease
Cancer
|
TSPO ligand-1 is the ligand of AUTAC4 (HY-134640) that can be used in the synthesis of PROTACs. TSPO ligand-1 is a mitochondrial outer membrane transmembrane structural domain protein can bind to AUTAC4 and regulate mitochondrial autophagy to promote targeted mitochondrial renewal. TSPO ligand-1 is also involved in the transport of cholesterol from the outer to inner mitochondrial membrane and serves as a sensitive biomarker of brain injury and neurodegeneration .
|
-
-
- HY-23212A
-
|
Others
|
Cancer
|
2-Amino-1,3-bis(carboxylethoxy)propane hydrochloride is a non-protein amino acid, sulfamic acid.2-Amino-1,3-bis(carboxylethoxy)propane hydrochloride contains one amino group and two terminal carboxylic acids.2-Amino-1,3-bis(carboxylethoxy)propane hydrochloride has a variety of physiological functions, including maintaining the stability of cell membranes, regulating cholesterol metabolism, supporting the normal function of the nervous system, participating in collagen synthesis, and anti-oxidation .
|
-
-
- HY-113259
-
|
Endogenous Metabolite
|
Metabolic Disease
|
7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
|
-
-
- HY-113259S
-
|
Endogenous Metabolite
|
Metabolic Disease
|
7α-Hydroxy-4-cholesten-3-one-d7 is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1[1][2].
|
-
-
- HY-113259R
-
|
Endogenous Metabolite
|
Metabolic Disease
|
7α-Hydroxy-4-cholesten-3-one (Standard) is the analytical standard of 7α-Hydroxy-4-cholesten-3-one. This product is intended for research and analytical applications. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1 .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-P5282
-
|
Drug Delivery
|
ApoA-I mimetic peptide (PVLDLFRELLNELLEALKQKLK) has good lecithin:cholesterol acyl transferase (LCAT) activation potency. ApoA-I mimetic peptide can be used for synthesis of peptide/lipid complex .
|
-
- HY-114294A
-
|
Biochemical Assay Reagents
|
DL-3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) disodium is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor .
|
-
- HY-N7392
-
|
Biochemical Assay Reagents
|
Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P5282
-
|
Liposome
|
Others
|
ApoA-I mimetic peptide (PVLDLFRELLNELLEALKQKLK) has good lecithin:cholesterol acyl transferase (LCAT) activation potency. ApoA-I mimetic peptide can be used for synthesis of peptide/lipid complex .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-124265S2
-
|
4β-Hydroxycholesterol-d4 is the deuterium labeled 4β-Hydroxycholesterol. 4β-hydroxy Cholesterol is a major oxysterol cholesterol metabolite and a precursor in the synthesis of bile acids that is found in human circulation[1][2].
|
-
-
- HY-113486S1
-
|
lathosterol-d7 is deuterium labeled lathosterol. Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis[1].
|
-
-
- HY-113486S
-
|
(S)-Lathosterol-d4 is the deuterium labeled (S)-Lathosterol. Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis[1].
|
-
-
- HY-W020033S
-
|
Lanosterol-d6 is deuterium labeled Lanosterol. Lanosterol is an intermediate of cholesterol synthesis and use of lanosterol induces ubiquitination and degradation of a rate-controlling enzyme of cholesterol synthesis, i.e., HMG CoA reductase. Lanosterol s
|
-
-
- HY-124265S1
-
|
4β-Hydroxycholesterol-d5 is the deuterium labeled 4β-Hydroxycholesterol (HY-124265). 4β-hydroxy Cholesterol is a major oxysterol cholesterol metabolite and a precursor in the synthesis of bile acids that is found in human circulation[1][2].
|
-
-
- HY-N1214S
-
|
Squalene-d6 is a deuterium labeled Squalene. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity .
|
-
-
- HY-B0144AS1
-
|
Pitavastatin-d5 (sodium) is the deuterium labeled Pitavastatin sodium. Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
|
-
-
- HY-B0144S
-
|
Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity[1][2][3].
|
-
-
- HY-113259S
-
|
7α-Hydroxy-4-cholesten-3-one-d7 is the deuterium labeled 7α-Hydroxy-4-cholesten-3-one. 7α-Hydroxy-4-cholesten-3-one is an intermediate in synthesis of bile acids from cholesterol. 7α-Hydroxy-4-cholesten-3-one is a pregnane X receptor (PXR) agonist. 7α-Hydroxy-cholest-4-en-3-one is a biomarker for bile acid loss, irritable bowel syndrome, and other diseases associated with defective bile acid biosynthesis. 7α-Hydroxy-cholest-4-en-3-one is the physiological substrate for CYP8B1[1][2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: